DK1771474T3 - Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf - Google Patents

Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf

Info

Publication number
DK1771474T3
DK1771474T3 DK05790352.8T DK05790352T DK1771474T3 DK 1771474 T3 DK1771474 T3 DK 1771474T3 DK 05790352 T DK05790352 T DK 05790352T DK 1771474 T3 DK1771474 T3 DK 1771474T3
Authority
DK
Denmark
Prior art keywords
protein
combinations
angiopoitin
inhibitors
cancer
Prior art date
Application number
DK05790352.8T
Other languages
English (en)
Inventor
Napoleone Ferrara
Hans-Peter Gerber
Xiao Huan Liang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35787710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1771474(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1771474T3 publication Critical patent/DK1771474T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
DK05790352.8T 2004-07-20 2005-07-19 Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf DK1771474T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58978204P 2004-07-20 2004-07-20
PCT/US2005/025734 WO2006014729A2 (en) 2004-07-20 2005-07-19 Inhibitors of angiopoietin-like 4 protein, combinations, and their use

Publications (1)

Publication Number Publication Date
DK1771474T3 true DK1771474T3 (da) 2010-05-31

Family

ID=35787710

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05790352.8T DK1771474T3 (da) 2004-07-20 2005-07-19 Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf

Country Status (23)

Country Link
US (2) US7740846B2 (da)
EP (3) EP1771474B1 (da)
JP (2) JP4947717B2 (da)
KR (1) KR101254815B1 (da)
CN (2) CN102641503A (da)
AT (1) ATE456579T1 (da)
AU (2) AU2005269716B2 (da)
BR (1) BRPI0513534A (da)
CA (1) CA2574758A1 (da)
CY (1) CY1109931T1 (da)
DE (1) DE602005019167D1 (da)
DK (1) DK1771474T3 (da)
ES (1) ES2339789T3 (da)
IL (1) IL180725A0 (da)
MX (1) MX2007000784A (da)
NO (1) NO20070951L (da)
NZ (1) NZ552956A (da)
PL (1) PL1771474T3 (da)
PT (1) PT1771474E (da)
RU (1) RU2392966C2 (da)
SI (1) SI1771474T1 (da)
WO (1) WO2006014729A2 (da)
ZA (1) ZA200701183B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7883720B2 (en) 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
HUE029170T2 (en) 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
ZA200705980B (en) * 2005-01-07 2009-01-28 Lexicon Pharmaceuticals Inc Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4)
US8734851B2 (en) * 2005-04-29 2014-05-27 Wisconsin Alumni Research Foundation Localized delivery of nucleic acid by polyelectrolyte assemblies
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR100962301B1 (ko) 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
SI2101807T1 (sl) * 2006-12-19 2016-08-31 Genentech, Inc. VEGF-specifični antagonisti za adjuvansno in neoadjuvansno terapijo in zdravljenje tumorjev v zgodnjem stadiju
US8834918B2 (en) * 2007-01-22 2014-09-16 Wisconsin Alumni Research Foundation Modified multilayered film
CN101842095B (zh) * 2007-07-02 2015-06-24 于明 肿瘤治疗的配方,方法和靶目标
US20090105375A1 (en) * 2007-10-09 2009-04-23 Lynn David M Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
US8126437B1 (en) 2008-01-24 2012-02-28 Invent Again Ubiquitous voice messaging
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
CA2730742C (en) * 2008-07-16 2017-05-23 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
AU2009316409A1 (en) 2008-11-22 2010-05-27 Genentech, Inc. Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
DK2451279T3 (da) 2009-07-06 2019-05-20 Aerpio Therapeutics Inc Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller
EP2488640B1 (en) 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
AU2011203986C1 (en) 2010-01-08 2015-03-05 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US9139629B2 (en) * 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
ES2877629T3 (es) * 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
US20140004209A1 (en) 2010-12-22 2014-01-02 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
KR20140072026A (ko) 2011-07-22 2014-06-12 페이실렉스 파마슈티컬스 인코포레이티드 암의 합성치사 및 치료
SG10201607346XA (en) * 2011-08-08 2016-10-28 Univ Nanyang Tech Angiopoietin-like 4 and its use in modulating cell leakiness
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
EP2885319B1 (en) * 2012-08-14 2019-10-09 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
US9259435B2 (en) 2012-08-31 2016-02-16 W. L. Gore & Associates, Inc. Reactive oxidative species generating materials and methods of use
JP6463685B2 (ja) * 2012-10-30 2019-02-06 パシレックス・ファーマシューティカルズ・インコーポレイテッド 合成致死性および癌の治療
KR101407730B1 (ko) * 2012-11-23 2014-06-12 인하대학교 산학협력단 안지오포이에틴-4 단백질을 유효성분으로 포함하는 발기부전의 예방 또는 치료용 조성물
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CN111593051A (zh) 2013-05-01 2020-08-28 Ionis制药公司 组合物和方法
CA2931510A1 (en) 2013-12-24 2015-07-02 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US9994560B2 (en) 2014-03-14 2018-06-12 Aerpio Therapeutics, Inc. HPTP-β inhibitors
EP3137605B1 (en) 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
PT3177642T (pt) * 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
CN106596979B (zh) * 2017-02-28 2018-10-09 汉氏联合（天津）干细胞研究院有限公司 一种用于帕金森综合症检测的试剂盒及其检测方法
CN113015803A (zh) * 2018-11-13 2021-06-22 利皮药业有限公司 影响脂肪酸代谢调控的angptl4寡核苷酸
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CA3164050A1 (en) * 2019-12-09 2021-06-17 Empirico Inc. Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases
CN112611877B (zh) * 2020-12-31 2022-09-16 四川大学华西医院 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒
CN113797355B (zh) * 2021-10-14 2023-07-21 四川大学华西医院 具有滑膜炎症抑制功能的纳米材料的制备方法及应用

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ500078A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
BRPI9809388B8 (pt) 1997-04-07 2021-05-25 Genentech Inc anticorpos humanizados e métodos para a formação de anticorpos humanizados.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6348350B1 (en) * 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US20030207375A1 (en) 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1931599A (en) 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
JP2002516067A (ja) 1998-03-02 2002-06-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド 新規ｆｄｒｇタンパク質および核酸分子、ならびにそのための用途
JP2002518010A (ja) * 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
JP4650976B2 (ja) 1998-07-15 2011-03-16 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 生物学的テンプレート上の高分子電解質
US6375447B1 (en) 1998-09-29 2002-04-23 Cq Inc. Apparatus for dewatering and pelletizing particulate fuel
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2000308488A (ja) 1999-02-23 2000-11-07 Herikkusu Kenkyusho:Kk 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子
AU3391200A (en) 1999-03-04 2000-09-21 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
JP2003501011A (ja) 1999-04-09 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４９個のヒト分泌タンパク質
KR100634926B1 (ko) 1999-04-16 2006-10-17 제넨테크, 인크. 혈관 내피 세포 성장 인자 변이체 및 그의 용도
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU5979300A (en) 1999-07-02 2001-01-22 Bayer Aktiengesellschaft Angiopoietin-6 and uses thereof
WO2001005825A2 (en) 1999-07-16 2001-01-25 Hyseq, Inc. Nucleic acid sequences encoding putative angiopoietin proteins
CA2379925A1 (en) 1999-07-20 2001-01-25 Curagen Corporation Polypeptides and polynucleotides encoding same
US20030207348A1 (en) * 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
CN1315451A (zh) 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸
WO2001077151A2 (en) 2000-04-07 2001-10-18 Millennium Pharmaceuticals, Inc. Fdrg proteins and nucleic acid molecules and uses therefor
IL152794A0 (en) 2000-06-23 2003-06-24 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
CN1170850C (zh) * 2000-09-19 2004-10-13 上海市肿瘤研究所 人血管生成素样蛋白和编码序列及其用途
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
WO2003000865A2 (en) 2001-03-27 2003-01-03 Human Genome Sciences, Inc. Human secreted proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
CA2444098C (en) 2001-04-19 2016-06-21 The Scripps Research Institute Methods and composition for the production of orthogonal trna-aminoacyltrna synthetase pairs
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2002101039A1 (en) 2001-06-08 2002-12-19 Sankyo Company, Limited Method of testing drug for treating or preventing diseases such as hyperlipemia
WO2003010205A1 (en) 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
JP2005518782A (ja) 2001-09-17 2005-06-30 プロテイン デザイン ラブス， インコーポレイテッド ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040038230A1 (en) 2001-11-05 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2460653A1 (en) 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2002348286B2 (en) * 2001-11-16 2008-04-03 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 Angptl3
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050239706A1 (en) * 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2499791A1 (en) * 2004-03-30 2005-09-30 F. Hoffmann-La Roche Ag Angptl4/fiaf as marker for ppardelta modulation
HUE029170T2 (en) 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
ZA200705980B (en) * 2005-01-07 2009-01-28 Lexicon Pharmaceuticals Inc Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4)

Also Published As

Publication number Publication date
AU2005269716B2 (en) 2011-01-27
AU2005269716A1 (en) 2006-02-09
AU2011201436A1 (en) 2011-04-21
EP2172482A1 (en) 2010-04-07
RU2007106076A (ru) 2008-08-27
EP1771474A2 (en) 2007-04-11
EP2361931B1 (en) 2017-12-06
JP4947717B2 (ja) 2012-06-06
NO20070951L (no) 2007-04-20
JP2012017331A (ja) 2012-01-26
MX2007000784A (es) 2007-04-09
DE602005019167D1 (de) 2010-03-18
EP2361931A1 (en) 2011-08-31
PT1771474E (pt) 2010-05-03
CN101044164A (zh) 2007-09-26
IL180725A0 (en) 2007-06-03
RU2392966C2 (ru) 2010-06-27
KR20070043010A (ko) 2007-04-24
ZA200701183B (en) 2008-05-28
SI1771474T1 (sl) 2010-06-30
NZ552956A (en) 2010-03-26
EP1771474B1 (en) 2010-01-27
CN102641503A (zh) 2012-08-22
KR101254815B1 (ko) 2013-09-03
WO2006014729A3 (en) 2007-01-04
JP2008507536A (ja) 2008-03-13
PL1771474T3 (pl) 2010-07-30
US20070026002A1 (en) 2007-02-01
CA2574758A1 (en) 2006-02-09
US20060093607A1 (en) 2006-05-04
US7740846B2 (en) 2010-06-22
CY1109931T1 (el) 2014-09-10
BRPI0513534A (pt) 2008-05-06
ATE456579T1 (de) 2010-02-15
ES2339789T3 (es) 2010-05-25
WO2006014729A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
CY2017013I2 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE496636T1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
ATE538136T1 (de) Antikörper gegen connective tissue growth factor
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
TW200732347A (en) VEGF analogs and methods of use
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
IS6667A (is) Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
EA200802213A1 (ru) Способы лечения заболеваний крови
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
ATE410998T1 (de) Verwendung einer proteinkinase a-inaktivierenden verbindung in einer kosmetisch verträglichen zusammensetzung zur aufhellung der haut
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE527998T1 (de) Illudin-analoga als krebsmittel
NO20076241L (no) Terapier for vaskulaere sykdommer
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
ATE496921T1 (de) Isoflavonoiddimere
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
BRPI0821114A2 (pt) Composto, uso de um composto e método para tratar qualquer mamífero afetado por câncer
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
ATE522625T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker